Business Wire

Verimatrix to Showcase Game-Changing Cybersecurity Technology at IBC Conference

Share

Regulatory News:

Verimatrix, (Euronext Paris: VMX), the leader in powering the modern connected world with people-centered security, today announced it will highlight its powerful content protection, anti-piracy and enterprise cybersecurity technologies for streaming services providers, broadcasters, telcos and operators from September 9-12 during this year’s IBC conference at RAI Amsterdam.

The company’s IBC showcase follows a fast-growing number of technology partnerships that underscore the appeal of the cloud-based Verimatrix Streamkeeper solution that’s designed to enable battle-ready, yet streamlined and cost-effective protections for content delivered via nearly any platform type. The IBC conference serves as one of the media and entertainment industry’s most notable venues to feature Verimatrix’s unique zero-code telemetry approach that makes anti-piracy and cybersecurity not only simple and fast, but also cost-effective and designed to encourage integration with other related M&E providers.

IBC Show Highlights:

- Product demos - Verimatrix XTD (Extended Threat Defense), Verimatrix Streamkeeper, Verimatrix Secure Delivery Platform and Verimatrix VCAS (IPTV/DVB)
- 3D hologram – A holographic presentation of Verimatrix Counterspy, the company’s proprietary anti-piracy and app protection security agent that uses proprietary zero code technology
- Partner recognition – Technology partners are critical to Verimatrix’s success, and the company will feature key partners on its partner wall, during demos and in booth videos

The company is set to host two in-booth mixers at its IBC Booth 1.C23 on September 9 and 10 with TiVo, a leader in DVR and advanced television, as well as The Goose House, a popular esports community that Verimatrix sponsors. Verimatrix is also sponsoring a Media and Entertainment Services Alliance (MESA) networking event scheduled for 8-10 p.m. on September 9 at Café Black.

“Today’s countless ways of delivering and consuming entertainment require a modern approach to anti-piracy and cyberattack prevention, but they must be offered as business enablers and value providers versus costs centers. Verimatrix Streamkeeper and Verimatrix XTD are two new solutions engineered to do just that,” said Asaf Ashkenazi, CEO at Verimatrix. “Our theme for IBC 2022 is ‘STREAM ON! Game changing security for streaming & beyond’ and we are excited to showcase a stunning new booth design where we will showcase our latest products alongside our award-winning, legacy content security solutions.”

Verimatrix Streamkeeper stands as a cybersecurity and anti-piracy gamechanger. Its users can implement a comprehensive set of content protection and anti-piracy solutions such as Multi-DRM, Watermarking, App Shield and other countermeasures that allow users to hunt down and take out OTT pirates who often take advantage of premium content that’s left unprotected. Streamkeeper includes Verimatrix's Counterspytechnology – the autonomous injection of an anti-piracy and app protection security agent that uses proprietary zero code technology that brings deep, defensive countermeasures as well as the monitoring of clients without the hassle of a huge integration effort.

Verimatrix XTD defends against endpoint attacks by monitoring apps, APIs and unmanaged devices; illuminating blind spots and preventing firewall intrusions -- threats that are not typically covered by existing cybersecurity solutions.

Verimatrix Streamkeeper info is available at www.verimatrix.com/products/streamkeeper.
Verimatrix XTD info is available at www.verimatrix.com/products/extended-threat-defense.

About Verimatrix
Verimatrix (Euronext Paris: VMX) helps power the modern connected world with security made for people. We protect digital content, applications, and devices with intuitive, people-centered and frictionless security. Leading brands turn to Verimatrix to secure everything from premium movies and live streaming sports, to sensitive financial and healthcare data, to mission-critical mobile applications. We enable the trusted connections our customers depend on to deliver compelling content and experiences to millions of consumers around the world. Verimatrix helps partners get to market faster, scale easily, protect valuable revenue streams, and win new business. Visit www.verimatrix.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Verimatrix Investor Contact:
Jean-François Labadie, Chief Financial Officer
finance@verimatrix.com

Verimatrix Media Contact:
Matthew Zintel
matthew.zintel@zintelpr.com

About Business Wire

Business Wire
Business Wire



Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

HCLTech Reports FY24 Revenue of $13.3 Billion, up 5.4% YoY26.4.2024 22:06:00 CEST | Press release

HCLTech, a leading global technology company, today reported financial results for the fourth quarter and the full year ended March 31, 2024. The company reported full year revenue of $13.3 billion, up 5.4% YoY. Digital Services revenue grew by 5.3% (CC) and now contributes to 37.3% of IT Services revenue. HCLSoftware’s Annual Recurring Revenue came in at $1.02 billion. During FY24, the company won 73 large deals – 36 in Services and 37 in Software - that translated into TCV (new deal wins) of $9.76 billion, up 10% YoY. For the quarter, revenue came in at $3.43 billion, up 6% YoY. HCLTech won 21 large deals – 13 in Services and eight in Software, with a TCV of $2.29 billion during the quarter. In terms of geographies, Americas was the fastest growing region with 6.8% YoY (CC) growth followed by Europe, which grew by 5.5% YoY (CC). Industry vertical growth was led by Financial Services and Telecommunications, Media, Publishing & Entertainment. While Financial Services grew at 12.1% YoY

Kinaxis Positioned Highest on Ability to Execute in the Gartner® Magic Quadrant™ for Supply Chain Planning Solutions26.4.2024 18:03:00 CEST | Press release

Kinaxis® Inc. (TSX:KXS), a global leader in end-to-end supply chain orchestration, today announced it has been named a Leader in the 2024 Gartner® Magic Quadrant™ for Supply Chain Planning Solutions. Of the 20 vendors evaluated, Gartner positioned Kinaxis highest on Ability to Execute, marking the company’s 10th consecutive Leaders Quadrant within the report, a complimentary copy of which can be downloaded here. Kinaxis attributes its position to its patented concurrency approach and a proven track record of delivering innovative solutions against the foundation of its leading vision through the use of advanced technology such as AI, ML, and an intuitive user experience. Bolstered by a rich ecosystem of third-party implementation partners, Kinaxis continues to demonstrate that regardless of a customer’s industry, size, or maturity level, the company can be counted on to seamlessly orchestrate supply chain networks end-to-end from strategic planning to last-mile delivery. The recognitio

Vertex Announces European Commission Approval for KALYDECO ® to Treat Infants With Cystic Fibrosis Ages 1 Month and Older26.4.2024 17:43:00 CEST | Press release

Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Commission has granted approval for the label expansion of KALYDECO® (ivacaftor) for the treatment of infants down to 1 month of age with cystic fibrosis (CF) who have one of the following mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene: R117H, G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N or S549R. “Today’s approval is an important milestone for the cystic fibrosis community. Treating CF early in life can potentially slow the progression of the disease, which is why it is so important to start treatment from a very young age,” said Carmen Bozic, M.D., Executive Vice President, Global Medicines Development and Medical Affairs, and Chief Medical Officer, Vertex. As a result of existing access agreements in Austria, Czech Republic, Denmark, Ireland, Norway, Sweden, and The Netherlands, eligible patients will have access to the expanded indication of KALYDECO® (ivacaftor)

Suzano 2023 annual report on Form 20-F26.4.2024 17:22:00 CEST | Press release

Suzano S.A. (B3: SUZB3 | NYSE: SUZ) informs that its 2023 Annual Report on Form 20-F was filed today with the U.S. Securities and Exchange Commission. Holders of the Company’s equity securities can receive hard copies of the Annual Report, including its audited financial statements, without charge by request directed to: ri@suzano.com.br. This document is also available on Suzano’s website (http://ir.suzano.com.br/). For further information, please contact our Investor Relations Department: Phone: (+55 11) 3503-9330 E-mail: ri@suzano.com.br View source version on businesswire.com: https://www.businesswire.com/news/home/20240426289818/en/Contact information Hawthorn Advisors suzano@hawthornadvisors.com

Takeda Receives Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer26.4.2024 14:30:00 CEST | Press release

Takeda (TSE:4502/NYSE:TAK) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of fruquintinib, a selective inhibitor of vascular endothelial growth factor receptors (VEGFR) -1, -2 and -3 for the treatment of adult patients with previously treated metastatic colorectal cancer (mCRC). The European Commission (EC) will consider the CHMP positive opinion when determining the potential marketing authorization for fruquintinib for mCRC throughout the European Union (EU), Norway, Liechtenstein and Iceland. If approved, fruquintinib will be the first and only selective inhibitor of all three VEGF receptors approved in the EU for previously treated mCRC.1,2 “People living with metastatic colorectal cancer in the European Union currently have limited treatment options, which can lead to poor outcomes. With this positive opinion for fruquintinib, we are one step closer to potentially offering patients a new

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
HiddenA line styled icon from Orion Icon Library.Eye